BRPI0406499A - Insulina de longa atuação para redução da morbidez e mortalidade cardiovascular em pacientes pré-diabéticos e pacientes com diabetes tipo 2 - Google Patents

Insulina de longa atuação para redução da morbidez e mortalidade cardiovascular em pacientes pré-diabéticos e pacientes com diabetes tipo 2

Info

Publication number
BRPI0406499A
BRPI0406499A BR0406499-2A BRPI0406499A BRPI0406499A BR PI0406499 A BRPI0406499 A BR PI0406499A BR PI0406499 A BRPI0406499 A BR PI0406499A BR PI0406499 A BRPI0406499 A BR PI0406499A
Authority
BR
Brazil
Prior art keywords
patients
type
mortality
diabetes
long
Prior art date
Application number
BR0406499-2A
Other languages
English (en)
Inventor
Ralf Rosskamp
Hertzel Gerstein
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of BRPI0406499A publication Critical patent/BRPI0406499A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"INSULINA DE LONGA ATUAçãO PARA REDUçãO DA MORBIDEZ E MORTALIDADE CARDIOVASCULAR EM PACIENTES PRé-DIABéTICOS E PACIENTES COM DIABETES TIPO 2". A presente invenção refere-se a um método para redução da morbidez e mortalidade cardiovascular em uma população de paciente de Diabetes Tipo 2 ou pré-diabética. O método compreende administrar uma dosagem eficaz de uma insulina de longa atuação, preferivelmente, insulina glargina, a um paciente de Diabetes Tipo 2 ou pré-diabético.
BR0406499-2A 2003-01-14 2004-01-14 Insulina de longa atuação para redução da morbidez e mortalidade cardiovascular em pacientes pré-diabéticos e pacientes com diabetes tipo 2 BRPI0406499A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43994103P 2003-01-14 2003-01-14
PCT/US2004/000879 WO2004064862A1 (en) 2003-01-14 2004-01-14 Long acting insulin for reducing cardiovascular morbidity and mortality in prediabetic patients and patients with type 2 diabetes

Publications (1)

Publication Number Publication Date
BRPI0406499A true BRPI0406499A (pt) 2005-12-06

Family

ID=23746761

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406499-2A BRPI0406499A (pt) 2003-01-14 2004-01-14 Insulina de longa atuação para redução da morbidez e mortalidade cardiovascular em pacientes pré-diabéticos e pacientes com diabetes tipo 2

Country Status (16)

Country Link
US (4) US7405196B2 (pt)
EP (2) EP2596800B1 (pt)
JP (1) JP5389325B2 (pt)
AU (2) AU2004206829B2 (pt)
BR (1) BRPI0406499A (pt)
CA (1) CA2512820C (pt)
CY (1) CY1118738T1 (pt)
DK (1) DK2596800T3 (pt)
ES (1) ES2604359T3 (pt)
GB (1) GB0309154D0 (pt)
HU (1) HUE031892T2 (pt)
IL (3) IL169697A (pt)
MX (1) MXPA05007470A (pt)
PT (1) PT2596800T (pt)
SI (1) SI2596800T1 (pt)
WO (1) WO2004064862A1 (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
DK1648933T3 (da) * 2003-07-25 2009-09-07 Conjuchem Biotechnologies Inc Langvarige insulinderivater og fremgangsm der
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
KR101644250B1 (ko) 2004-08-23 2016-07-29 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
CN104324362B (zh) 2005-09-14 2018-04-24 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
IN2015DN00888A (pt) 2006-02-22 2015-07-10 Mannkind Corp
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
KR101628410B1 (ko) 2008-06-20 2016-06-08 맨카인드 코포레이션 흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
US10456036B2 (en) * 2008-12-23 2019-10-29 Roche Diabetes Care, Inc. Structured tailoring
KR20110097889A (ko) 2008-12-23 2011-08-31 에프. 호프만-라 로슈 아게 수집 디바이스 상에서 구동하는 구조화된 수집 절차의 구현, 실행, 데이터 수집, 및 데이터 분석을 위한 관리 방법 및 시스템
US8849458B2 (en) * 2008-12-23 2014-09-30 Roche Diagnostics Operations, Inc. Collection device with selective display of test results, method and computer program product thereof
US10437962B2 (en) 2008-12-23 2019-10-08 Roche Diabetes Care Inc Status reporting of a structured collection procedure
US9918635B2 (en) 2008-12-23 2018-03-20 Roche Diabetes Care, Inc. Systems and methods for optimizing insulin dosage
US20120011125A1 (en) 2008-12-23 2012-01-12 Roche Diagnostics Operations, Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
US9117015B2 (en) 2008-12-23 2015-08-25 Roche Diagnostics Operations, Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
CN104721825B (zh) 2009-06-12 2019-04-12 曼金德公司 具有确定比表面积的二酮哌嗪颗粒
CN102596175A (zh) 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
US8532933B2 (en) 2010-06-18 2013-09-10 Roche Diagnostics Operations, Inc. Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
IL223742A (en) 2010-06-21 2016-06-30 Mannkind Corp A dry powder inhaler and preparation for it
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
US20120173151A1 (en) 2010-12-29 2012-07-05 Roche Diagnostics Operations, Inc. Methods of assessing diabetes treatment protocols based on protocol complexity levels and patient proficiency levels
AU2012236150B2 (en) 2011-04-01 2016-03-31 Mannkind Corporation Blister package for pharmaceutical cartridges
US8766803B2 (en) 2011-05-13 2014-07-01 Roche Diagnostics Operations, Inc. Dynamic data collection
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US8755938B2 (en) 2011-05-13 2014-06-17 Roche Diagnostics Operations, Inc. Systems and methods for handling unacceptable values in structured collection protocols
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
JP2014533741A (ja) * 2011-12-01 2014-12-15 サノフイ 早期２型糖尿病の第一選択処置についてメトホルミンと対比したインスリングラルギン
JP2015512908A (ja) * 2012-03-28 2015-04-30 サノフイ 基礎インスリン療法
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
UA117480C2 (uk) 2013-04-03 2018-08-10 Санофі Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
WO2016001185A1 (en) * 2014-07-02 2016-01-07 Novo Nordisk A/S Dosage regimen for the treatment of diabetes
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US20180369342A1 (en) * 2015-12-23 2018-12-27 Sanofi-Aventis Deutschland Gmbh Cardiac metabolic effect of lantus
JP2019535791A (ja) 2016-11-28 2019-12-12 ノヴォ ノルディスク アー／エス 血糖コントロールの改善並びに急性及び長期糖尿病合併症の低減のためのインスリンデグルデク
US11278596B2 (en) 2016-11-28 2022-03-22 Novo Nordisk A/S Insulin degludec in cardiovascular conditions
WO2018096164A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
US11366189B2 (en) 2020-09-25 2022-06-21 Uih America, Inc. Systems and methods for magnetic resonance imaging
CN119833121B (zh) * 2025-01-09 2025-10-24 南通大学 一种糖尿病症状自动检测系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354331A (en) 1992-07-15 1994-10-11 Schachar Ronald A Treatment of presbyopia and other eye disorders
EP1000932B9 (en) * 1997-06-27 2005-12-28 Fujisawa Pharmaceutical Co., Ltd. Aromatic ring derivatives
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
EP1284723A4 (en) * 2000-04-19 2004-06-30 Borody Thomas J COMPILATIONS AND THERAPIES FOR HYPERLIPIDEMIA-ASSOCIATED DISEASES
WO2002034259A1 (en) * 2000-10-26 2002-05-02 Fournier Laboratories Ireland Limited Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction

Also Published As

Publication number Publication date
CA2512820A1 (en) 2004-08-05
IL169697A0 (en) 2007-07-04
MXPA05007470A (es) 2005-09-21
IL197739A (en) 2017-02-28
US20110281793A1 (en) 2011-11-17
AU2010202738A1 (en) 2010-07-22
CA2512820C (en) 2013-06-04
EP2596800B1 (en) 2016-08-24
GB0309154D0 (en) 2003-05-28
PT2596800T (pt) 2016-12-02
US20080287343A1 (en) 2008-11-20
WO2004064862A1 (en) 2004-08-05
DK2596800T3 (en) 2016-12-12
IL208525A0 (en) 2010-12-30
US8809270B2 (en) 2014-08-19
JP2006515625A (ja) 2006-06-01
US7977310B2 (en) 2011-07-12
ES2604359T3 (es) 2017-03-06
IL197739A0 (en) 2011-08-01
EP1589991A1 (en) 2005-11-02
US7405196B2 (en) 2008-07-29
SI2596800T1 (sl) 2017-04-26
HUE031892T2 (en) 2017-08-28
AU2010202738B2 (en) 2013-12-05
IL169697A (en) 2011-06-30
CY1118738T1 (el) 2017-07-12
AU2004206829A1 (en) 2004-08-05
AU2004206829B2 (en) 2010-04-08
US20040229774A1 (en) 2004-11-18
US20130012433A1 (en) 2013-01-10
EP2596800A1 (en) 2013-05-29
JP5389325B2 (ja) 2014-01-15

Similar Documents

Publication Publication Date Title
BRPI0406499A (pt) Insulina de longa atuação para redução da morbidez e mortalidade cardiovascular em pacientes pré-diabéticos e pacientes com diabetes tipo 2
BR0314799A (pt) Controle glicêmico aperfeiçoado para pré-diabetes e/ou diabetes do tipo ii usando ácido docosahexaenóico
BR9906796A (pt) Método para a administração de análogos de insulina monoméricos
MXPA05006994A (es) Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina.
ATE329586T1 (de) Zusammensetzungen enthaltend carotenoide und deren verwendung zur verhinderung hormon- induzierter nebenwirkungen
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BR0307540A (pt) Preparação farmacêutica em forma de filme ou em forma de lâmina para administrar substâncias ativas, uso da preparação farmacêutica e processo para a administração oral de substância(s) farmaceuticamente ativa(s) dotadas de sabor amargo
BR0207700A (pt) Método para tratar a diabete melito em um paciente em necessidade de tal tratamento, e, usos de um derivado de polipeptìdeo de insulina, e de um conjugado de polipeptìdeo de insulina-oligÈmero
BR0010750A (pt) Peptìdeos insulinotrópicos de longa duração
BRPI0518460A2 (pt) mÉtodo para tratar emergÊncia alÉrgica em um paciente, dispositivo de distribuiÇço de droga contendo uma soluÇço de epinefrina, e, kit para tratar uma emergÊncia alÉrgia'
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
UY27186A1 (es) Formulación farmacéutica
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
WO2003090671A3 (en) Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
NO20072931L (no) Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
SI1680128T1 (sl) Mio-inozitol heksafosfat za topično uporabo
MX2008004734A (es) Composicion rica en leucina.
DE602006020070D1 (de) Verringerung von schwindel, einer nebenwirkung im zusammenhang mit einer pirfenidon-therapie
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
BR0308229A (pt) Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio
DK1675611T3 (da) Terapeutiske anvendelser for C-peptid
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: AVENTIS PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070165509/RJ DE 23/11/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]